Riskpilot← Back to searchSign inGet full accessTakeda Pharma AB
ABActiveOrg 5561130302Hagaesplanaden 49Wholesale of pharmaceutical and medical goods · NACE 4646Est. 196750-99 employees
Revenue 2025
SEK 2,7B
+18% vs 2024
EBITDA margin
3.2%
+10% vs 2024
Equity ratio
28.8%
Financial strength
Net profit 2025
SEK 59,4M
+7% vs 2024
| Revenue | SEK 2,7B | +18% |
| EBITDA | SEK 86,3M | +10% |
| Net profit | SEK 59,4M | +7% |
| Total assets | SEK 1,3B | +43% |
| Equity | SEK 364,6M | +19% |
| Employees | — | — |
Legal name
Takeda Pharma AB
Org number
5561130302
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
13 november 1967
Share capital
SEK 2 000 000
Employees
50-99
VAT registered
Yes
Audit selected
No
Last report
2025-03-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Föremålet för bolagets verksamhet är att bedriva forsknings- och upplysningsverksamhet rörande läkemedel och pharmaceuptiska pro- dukter samt patentering, licensgivning, tillverkning och försälj- ning av sådana varor ävensom idka annan därmed förenlig verksam- het med rätt för bolaget att bedriva sin verksamhet genom del- ägarskap i andra företag.
Address
Hagaesplanaden 49
Phone
+46854496400
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 483 926 | 546 810 | 641 697 | 2 062 809 | 1 767 263 | 2 057 423 | 2 281 670 | 2 701 033 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 13 712 | 13 818 | 4 888 | 12 506 | 23 916 | 67 389 | 63 611 | 70 518 | 78 702 | 86 279 |
| Depreciation & amort. | −6 025 | −6 046 | −135 | −103 | −58 | −1 596 | −2 636 | −2 208 | −2 100 | −2 267 |
| EBIT | 7 687 | 7 772 | 4 753 | 12 403 | 23 858 | 65 793 | 60 975 | 68 310 | 76 602 | 84 012 |
| Net financials | −77 | −90 | −72 | −311 | 1 018 | 8 495 | −4 561 | −15 629 | −2 471 | −5 910 |
| Profit before tax | 7 758 | 7 863 | 4 681 | 12 864 | 41 288 | 75 636 | 60 479 | 62 404 | 74 469 | 78 209 |
| Tax | −1 578 | −1 961 | −1 252 | −3 413 | −9 129 | −16 507 | −12 983 | −14 074 | −18 861 | −18 835 |
| Net profit | 6 180 | 5 902 | 3 429 | 9 451 | 32 159 | 59 129 | 47 496 | 48 330 | 55 608 | 59 374 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 138 624 | 147 360 | 162 872 | 174 714 | 486 551 | 757 347 | 714 804 | 777 913 | 887 601 | 1 265 303 |
| Equity | 57 144 | 63 046 | 66 474 | 75 925 | 108 084 | 256 220 | 203 716 | 249 651 | 305 259 | 364 632 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 5 194 | 3 534 | 2 759 | 2 534 | 2 485 |
| Short-term debt | 64 115 | 67 130 | 79 214 | 82 377 | 378 467 | 495 933 | 507 554 | 525 503 | 579 809 | 898 186 |
| Total debt | 64 115 | 67 130 | 79 214 | 82 377 | 378 467 | 501 127 | 511 088 | 528 262 | 582 343 | 900 671 |
EBITDA margin
3.2%
This company
15.8%
Market median
-80% vs market
20162025
Equity ratio
28.8%
This company
38.2%
Market median
-25% vs market
20162025
Return on equity
16.3%
This company
18.4%
Market median
+11% vs market
20162025
Net profit margin
2.2%
This company
8.1%
Market median
-73% vs market
20162025
Asset turnover
2.13×
This company
1.12×
Market median
+90% vs market
20162025
Debt / equity
2.47×
This company
0.62×
Market median
-298% vs market
20162025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-04-01 – 2021-03-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-04-01 – 2020-03-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-04-01 – 2019-03-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-04-01 – 2018-03-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-04-01 – 2017-03-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-04-01 – 2016-03-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AJ Chief Auditor | Chief Auditor | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2025 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
TAKEDA PHARMACCEUTICALS INTERNATIONAL AG | Company | 100.0% | 100.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
TAKEDA PHARMACCEUTICALS INTERNATIONAL AG
Takeda Pharma AB (this company)Board members of Takeda Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anders Joakim Toivo Taaler | Chief Auditor | 0 companies |
| Koki Sato | Board of Directors | 0 companies |
| Per Niklas William Rydingsvärd | Board of Directors | 0 companies |
| Roland Kurney | Chairman | 0 companies |
| Sofia Therese Hultman | Board of Directors | 0 companies |
| Silvia Gabriele Bäckström | Board of Directors | 0 companies |
| Vatroslav Mateljic | Chairman | 0 companies |
| Øyvind Løkeberg | Board of Directors | 0 companies |